Walleye Trading’s Relmada Therapeutics RLMD Stock Holding History

Walleye Trading’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,334	Closed	-$43K	–	5302
2022 Q4	$43K	Buy	+12,334	New	+$108K	﹤0.01%	4233

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Trading's RLMD Position: Q1 2023 in Review

Walleye Trading sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 12,334 shares — an estimated $43K sold.

Walleye Trading first reported a position in RLMD in Q4 2022 and held it in 1 quarter. The position peaked at $43K in Q4 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

Walleye Trading reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
Walleye Trading sold 12,334 Relmada Therapeutics shares in Q1 2023, an estimated $43K.
Walleye Trading first reported a position in Relmada Therapeutics in Q4 2022 and held it in 1 quarter.
Walleye Trading's Relmada Therapeutics position peaked at $43K in Q4 2022.
91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Walleye Trading's 13F filing for Q1 2023, filed 15 May 2023.